Daptomycin: Difference between revisions
From IDWiki
No edit summary |
No edit summary |
||
| Line 15: | Line 15: | ||
*Concentration-dependent, best predicted by AUC<sub>24</sub>:MIC |
*Concentration-dependent, best predicted by AUC<sub>24</sub>:MIC |
||
== Dosing == |
|||
* Standard dose: 6 mg/kg IV q24h |
|||
* High dose for severe infections, including [[MRSA bacteremia]]: 8 to 10 mg/kg IV q24h |
|||
=== Renal Dosing === |
|||
{| class="wikitable" |
|||
!GFR (mL/min) |
|||
!Routine Dose |
|||
!High Dose |
|||
|- |
|||
|>50 |
|||
|6 mg/kg IV q24h |
|||
|8-10 mg/kg IV q24h |
|||
|- |
|||
|11-50 |
|||
| |
|||
|6-8 mg/kg IV q24h |
|||
|- |
|||
|≤10 |
|||
| |
|||
|8 mg/kg IV q48h |
|||
|- |
|||
|HD |
|||
| |
|||
|8 mg/kg IV q48h, dosed after dialysis |
|||
|- |
|||
|CRRT |
|||
| |
|||
|8 mg/kg IV q48h |
|||
|} |
|||
[[Category:Cyclic lipopeptides]] |
[[Category:Cyclic lipopeptides]] |
||
Revision as of 20:13, 30 August 2022
Background
- Cyclic lipopeptide antibiotic that is active against Gram-positive bacteria
Mechanism of Action
- Mechanism of action is to depolarize the cell membrane
Pharmacokinetics and Pharmacodynamics
- Distributes well into soft tissues and musculoskeletal system, as well as urine
- Poor CNS penetration1
- Good lung penetration, but is inactivated by lung surfactant and should not be used to treat pneumonia
- Bactericidal
- Concentration-dependent, best predicted by AUC24:MIC
Dosing
- Standard dose: 6 mg/kg IV q24h
- High dose for severe infections, including MRSA bacteremia: 8 to 10 mg/kg IV q24h
Renal Dosing
| GFR (mL/min) | Routine Dose | High Dose |
|---|---|---|
| >50 | 6 mg/kg IV q24h | 8-10 mg/kg IV q24h |
| 11-50 | 6-8 mg/kg IV q24h | |
| ≤10 | 8 mg/kg IV q48h | |
| HD | 8 mg/kg IV q48h, dosed after dialysis | |
| CRRT | 8 mg/kg IV q48h |
References
- ^ S. Piva, Antonello Di Paolo, Laura Galeotti, Francesco Ceccherini, Francesco Cordoni, Liana Signorini, Tommaso Togni, Amedeo De Nicolò, Frank A. Rasulo, Nazzareno Fagoni, N. Latronico, Antonio D’Avolio. Daptomycin Plasma and CSF Levels in Patients with Healthcare-Associated Meningitis. Neurocritical Care. 2019;31(1):116-124. doi:10.1007/s12028-018-0657-y.
